UK-based clinical stage biopharmaceutical company Destiny Pharma has reported positive results from a US clinical trial of exeporfinium chloride to treat people with colonised nasal staphylococcus aureus (SA) bacteria.

Exeporfinium chloride (XF-73) is developed as a preventive anti-bacterial drug, which is a synthetic dicationic porphyrin derivative with antibacterial activity.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, the two-stage clinical trial was conducted at the NIAID Clinical Trials Unit at Case Western Reserve University in Cleveland and at Anaheim Clinical Trials in California, US.

The trial is intended to determine the safety, tolerability, and efficacy of intra-nasally administered exeporfinium chloride gels.

"The support from NIAID made this study possible and we plan to progress this important new drug into the next stage of development and thereon to market."

The Part I portion of the study has suggested the safety of the administration of exeporfinium chloride to eight volunteers, which later proceeded to the Part II portion of the study.

The Part II trial was designed as a double-blinded, placebo controlled study that tested two exeporfinium chloride concentration gels and two viscosities applied to the nostrils for five days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Both of the dosages have exhibited a safe and tolerable profile with no drug detected in the bloodstream.

Destiny Pharma CEO Dr Bill Love said: "We are delighted with these results, which demonstrate that exeporfinium chloride is safe and well tolerated and has the potential to deliver the FDA / QIDP awarded US indication for the prevention post-surgical SA infection.

“The support from NIAID made this study possible and we plan to progress this important new drug into the next stage of development and thereon to market."

The anti-bacterial drug has demonstrated a rapid, anti-staphylococcal effect after being administrated for one day displaying comparable results against placebo in a sustained way.